Dr. Yaman Suleiman, MD

Dr. Suleiman practices at AdventHealth Winter Park in Winter Park, Florida.

Dr. Suleiman's NPI, 1003128703, was assigned on July 9, 2010. Dr. Suleiman graduated from Indiana University School Of Medicine in 2010. Dr. Suleiman holds Florida license ME116138.

Dr. Suleiman's primary practice is AdventHealth Winter Park, at 200 N Lakemont Ave, Winter Park, FL 32792 in Orange County. The practice phone is (407) 303-5600.

Dr. Suleiman's primary practice is AdventHealth Winter Park in Winter Park, Florida. Dr. Suleiman is also affiliated with AdventHealth Orlando. The medical group on file is Florida Cancer Specialists & Research Institute. Dmand AI also links Dr. Suleiman to 1 more hospital, 2 group practices and clinics, 1 home health agency and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Suleiman practices, 5 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Suleiman's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Suleiman is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Suleiman's licenses on file in 2 states: Florida and Indiana.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), immune deficiency disease and lung cancer among the conditions Dr. Suleiman treats.

CMS data shows 120,062 Medicare services from Dr. Suleiman across 49 procedure codes in 2024, for 802 Medicare patients. Medicare paid $1,790,866 for them.

CMS counts 802 Medicare patients who saw Dr. Suleiman in 2024. The largest group is 75 to 84, with 322 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 9% are also on Medicaid. Their average risk score is 2.14, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Suleiman's median patient age at 64, with 59% women.

In 2024, Dr. Suleiman wrote 2,152 Medicare Part D claims for 348 patients. 70% of them were for generic drugs. CMS names the drug for 1,808 of them, across 56 drugs with 11 or more claims each, at $4,184,027 in total drug cost. In 2023, CMS named 1,825 claims across 60 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Suleiman for performance year 2024, reported as part of a group. Dr. Suleiman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Suleiman as offering telehealth.

Dmand AI links 5 papers to Dr. Suleiman, published from 2012 to 2016. Dr. Suleiman's most frequent co-authors are Samir Mukundray Dalia, MD, Rafat Abonour, MD and David W. Croy, MD.

Dmand AI links Dr. Suleiman to 1 clinical trial. Conditions studied include Sarcoma and Neoplasms, Connective and Soft Tissue.

CMS Open Payments shows 439 general payments to Dr. Suleiman from 61 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 82% of the total. Novartis Pharmaceuticals Corporation paid the most, $2,138.

Dr. Suleiman graduated from Indiana University School Of Medicine in 2010.

Dr. Suleiman is in network with 16 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.